4 papers and 2 clinical trials exploring nitrous oxide as a treatment for major depressive disorder (mdd).
Nitrous oxide (N₂O) is a rapid-acting NMDA receptor antagonist with emerging evidence for antidepressant efficacy in treatment-resistant depression. Delivered as a 50% N₂O/50% O₂ inhalation mixture over one-hour sessions, it produces rapid mood improvements that can persist for days to weeks. Its established safety record in anesthesia, short session duration, minimal recovery time, and low cost position it as a potentially scalable alternative to IV ketamine and esketamine, though the psychiatric evidence base remains early-stage and no formal psychiatric indication exists. Key open questions include optimal dosing frequency, long-term durability, and the mechanism by which NMDA antagonism without intense psychedelic phenomenology produces antidepressant effects.
Full Nitrous Oxide profileMajor Depressive Disorder (MDD) represents a significant mental health challenge, with emerging research into the efficacy of psychedelics like psilocybin and ketamine offering new avenues for treatment. Recent studies have demonstrated the potential of these compounds to alleviate symptoms, particularly in treatment-resistant cases of MDD.
Full Major Depressive Disorder (MDD) profile